Member Info for comeonvog

Go quite when they have bought in. They fill the header with negative subjects then rec each others posts. Why are they posting here. trolls.

mostly palladium, is this metal not in deficit.

Palladium is now the most valuable of the four major precious metals as an acute shortage has driven prices to a record. A key component in pollution-control devices for cars and trucks, the metal has surged almost 80 percent since mid-August, making it more expensive than gold.20 Dec 2018

I wonder who else will now be looking at EUR ,this is like free advertising

One of China's largest investment banks and VTB Capital, one of Russia's largest investment banks (together the "Banks")

Our total resource with the account of areas within the flanks contours is about 15 Moz of PGM (mostly palladium) that we believe puts us in a completely different league of major palladium companies already in production stage."

Woodford down to his last dregs.

Think stock will be hard come by on next news in q4....

Mereo's lead rare disease product candidate, setrusumab, is being developed for the treatment of osteogenesis imperfecta ("OI") with topline 12-month results from a Phase 2b dose ranging study expected in Q4 2019. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") with topline data expected in mid-2020.

I do like this part though. In line with the Company's strategy, a range of strategic partnering discussions have been initiated to provide additional funding for the navicixizumab program.

Ask now 54.75p.

Now showing 12% down, might be time to buy. ?? More news Q4

Mereo's lead rare disease product candidate, setrusumab, is being developed for the treatment of osteogenesis imperfecta ("OI") with topline 12-month results from a Phase 2b dose ranging study expected in Q4 2019. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD") with topline data expected in mid-2020.

This designation follows our successful Type B End of Phase 1 meeting with the FDA held in July 2019 regarding a potential pathway for accelerated approval for navicixizumab where the FDA agreed in principle on an outline for a Phase 2 clinical trial that could potentially support accelerated approval of navicixizumab in patients with ovarian cancer who have become resistant to prior therapies."

in principle ,could potentially. Might be a long hold.

Again. buying at 215p live but i can get a quote on Barclays for 209p.

We are going to get some hefty delayed trades , this jumping round hides an agenda IMO. Bid is moving higher.

Now back to 214.5p Ask

Today, i have been getting 213.5p to buy when trades have been going through at 207/8p. Very strange. Caught up now and i have 210 Ask .

If the potiticians really cared they would call a truce and sort this mess out together. As previous stated they are only out to seek power for their own agenda . IMO

calamari And you know this for a fact. Na didnt think so. Gives plenty of time to thrash out a deal. IMO

members i agree , poo further to drop. I am out of O&G till next year or a trade deal.

members I hope you realise they do that every month.

Company's all-employee Share Incentive Plan.

SuperRoty TBH i think they have given every indication they need capital. When in these circumstances do they ever look out for PI's . I will be looking at this once all is clear on that front,did warn at 6.8p+ .

I have also been stung with MTRO, got my av down to 305p with heavy trading then bang down it went this week. This market is truly fuc@ed with shorters running amok.

coffeecups it was in 2008 , slightly different circumstances to now.